Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2017

Rieken M, Shariat SF, Karam JA, Foerster B, Khani F, Gust K, et al. Frequency and Prognostic Value of PTEN Loss in Patients with Upper Tract Urothelial Carcinoma Treated with Radical Nephroureterectomy. J Urol. 2017;198(6):1269-1277.

Mohammed KH, Ewaz A, Cohen C, Siddiqui MT. Double staining: diagnostic utility in non-small cell lung carcinoma in the era of tissue conservation. J Am Soc Cytopathol. 2017;6(4):170-175.

Pisapia DJ, Salvatore S, Pauli C, Hissong E, Eng K, Prandi D, et al. Next-Generation Rapid Autopsies Enable Tumor Evolution Tracking and Generation of Preclinical Models. JCO Precis Oncol. 2017;2017.

Gucalp A, Iyengar NM, Zhou XK, Giri DD, Falcone DJ, Wang H, et al. Periprostatic adipose inflammation is associated with high-grade prostate cancer. Prostate Cancer Prostatic Dis. 2017;20(4):418-423.

Sun Q, Calderon B, Zhao Z. Discrepancies between two immunoassays for the determination of MPO and PR3 autoantibodies. Clin Chim Acta. 2017;470:93-96.

Giunchi F, Jordahl K, Bollito E, Colecchia M, Patriarca C, D'Errico A, et al. Interpathologist concordance in the histological diagnosis of focal prostatic atrophy lesions, acute and chronic prostatitis, PIN, and prostate cancer. Virchows Arch. 2017;470(6):711-715.

Zimmon DS, Smith FB, Manheimer F, Fan C, Njiwaji C, Aksenov S, et al. Endoscopic multiple biopsy and rapid diagnosis by in situ fixation and histopathologic processing. Gastrointest Endosc. 2017;86(2):333-342.

Covach A, Patel S, Hardin H, Lloyd RV. Phosphorylated Mechanistic Target of Rapamycin (p-mTOR) and Noncoding RNA Expression in Follicular and Hürthle Cell Thyroid Neoplasm. Endocr Pathol. 2017;28(3):207-212.

Khani F, Epstein JI. In response to 'a plea for greater standardization' in intraductal carcinoma of the prostate: greater standardization requires greater evidence. Histopathology. 2017;70(6):1011-1013.

Linares JF, Cordes T, Duran A, Reina-Campos M, Valencia T, Ahn CS, et al. ATF4-Induced Metabolic Reprograming Is a Synthetic Vulnerability of the p62-Deficient Tumor Stroma. Cell Metab. 2017;26(6):817-829.e6.